文献速递泌尿男性生殖肿瘤

局限性前列腺癌男性中治疗方式、功能结局与基线特征和治疗相关后悔的关联

Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer.
PubMed 文献 · JAMA Oncol · 2022-01-01

这项基于人群的前瞻性队列研究纳入2072例局限性前列腺癌男性,评估治疗方式、功能结局与患者期望和治疗相关后悔的关联。5年时手术、放疗和主动监测的后悔率分别为16%、11%和7%;校正基线差异后,手术与后悔可能性增加相关(aOR 2.40),放疗则无显著关联(aOR 1.53)。当考虑患者报告功能结局的中介作用时,治疗方式与后悔无独立关联;性功能障碍、患者感知的疗效和不良反应与后悔显著相关。

要点

  • 5年治疗相关后悔率:手术16%、放疗11%、主动监测7%。
  • 校正基线后手术与后悔增加相关(aOR 2.40,95%CI 1.44-4.01),放疗无显著关联(aOR 1.53,95%CI 0.88-2.66)。
  • 性功能障碍、患者感知疗效和不良反应与后悔显著相关。

核心结论

  • 局限性前列腺癌患者中超过十分之一经历治疗相关后悔。
  • 不同治疗方式的后悔率差异似乎由功能结局和患者期望介导。
  • 作者认为,聚焦期望和治疗毒性的治疗准备应在共享决策背景下开展,并作为未来研究课题以检验其能否减少后悔。

研究设计与样本

  • 基于人群的前瞻性队列研究,使用比较手术和放疗效果分析队列中5个基于监测、流行病学和最终结果(SEER)的登记处。
  • 纳入2011年1月1日至2012年12月31日临床局限性前列腺癌男性,共2072例,中位年龄64岁(IQR 59-69)。
  • 数据分析时间为2020年8月2日至2021年3月1日。
  • 暴露为前列腺癌治疗,包括手术、放疗和主动监测。

主要发现

  • 5年治疗相关后悔:手术183例(16%)、放疗76例(11%)、主动监测20例(7%)。
  • 与主动监测相比并校正基线差异,手术与后悔可能性增加相关(aOR 2.40,95%CI 1.44-4.01),放疗无显著关联(aOR 1.53,95%CI 0.88-2.66)。
  • 考虑患者报告功能结局的中介作用时,治疗方式与后悔无独立关联。
  • 性功能障碍与后悔显著相关(性功能较基线变化的aOR 0.65,95%CI 0.52-0.81),其他患者报告功能结局无显著关联。
  • 与治疗前患者期望相比,患者感知的治疗疗效(aOR 5.40,95%CI 2.15-13.56)和不良反应(aOR 5.83,95%CI 3.97-8.58)与治疗相关后悔相关。

临床怎么用

  • 作者认为,聚焦期望和治疗毒性的治疗准备应在共享决策背景下开展,并作为未来研究课题以检验其能否减少后悔。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Treatment-related regret is an integrative, patient-centered measure that accounts for morbidity, oncologic outcomes, and anxiety associated with prostate cancer diagnosis and treatment. OBJECTIVE: To assess the association between treatment approach, functional outcomes, and patient expectations and treatment-related regret among patients with localized prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: This population-based, prospective cohort study used 5 Surveillance, Epidemiology, and End Results (SEER)-based registries in the Comparative Effectiveness Analysis of Surgery and Radiation cohort. Participants included men with clinically localized prostate cancer from January 1, 2011, to December 31, 2012. Data were analyzed from August 2, 2020, to March 1, 2021. EXPOSURES: Prostate cancer treatments included surgery, radiotherapy, and active surveillance. MAIN OUTCOMES AND MEASURES: Patient-reported treatment-related regret using validated metrics. Regression models were adjusted for demographic and clinicopathologic characteristics, treatment approach, and patient-reported functional outcomes. RESULTS: Among the 2072 men included in the analysis (median age, 64 [IQR, 59-69] years), treatment-related regret at 5 years after diagnosis was reported in 183 patients (16%) undergoing surgery, 76 (11%) undergoing radiotherapy, and 20 (7%) undergoing active surveillance. Compared with active surveillance and adjusting for baseline differences, active treatment was associated with an increased likelihood of regret for those undergoing surgery (adjusted odds ratio [aOR], 2.40 [95% CI, 1.44-4.01]) but not radiotherapy (aOR, 1.53 [95% CI, 0.88-2.66]). When mediation by patient-reported functional outcomes was considered, treatment modality was not independently associated with regret. Sexual dysfunction, but not other patient-reported functional outcomes, was significantly associated with regret (aOR for change in sexual function from baseline, 0.65 [95% CI, 0.52-0.81]). Subjective patient-perceived treatment efficacy (aOR, 5.40 [95% CI, 2.15-13.56]) and adverse effects (aOR, 5.83 [95% CI, 3.97-8.58]), compared with patient expectations before treatment, were associated with treatment-related regret. Other patient characteristics at the time of treatment decision-making, including participatory decision-making tool scores (aOR, 0.80 [95% CI, 0.69-0.92]), social support (aOR, 0.78 [95% CI, 0.67-0.90]), and age (aOR, 0.78 [95% CI, 0.62-0.97]), were significantly associated with regret. Results were comparable when assessing regret at 3 years rather than 5 years. CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that more than 1 in 10 patients with localized prostate cancer experience treatment-related regret. The rates of regret appear to differ between treatment approaches in a manner that is mediated by functional outcomes and patient expectations. Treatment preparedness that focuses on expectations and treatment toxicity and is delivered in the context of shared decision-making should be the subject of future research to examine whether it can reduce regret.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Wallis CJD, Zhao Z, Huang LC, et al. Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer. JAMA Oncol. 2022. PMID: 34792527. doi:10.1001/jamaoncol.2021.5160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。